Kv1.3 inhibition improves diabetes and diabetes-associated low-grade inflammation and cardiac electrical remodeling, resulting in more protection against cardiac arrhythmia compared to metformin. This evidence concerns the gene KCNA3 and cardiac rhythm disease.